AdvanCell operates a comprehensive partnership program for taking novel radioligand therapies from the lab through to Phase 1 and beyond.
AdvanCell provides its cGMP isotope to partners removing reliance on external supply chains.
AdvanCell’s in-house manufacturing team and infrastructure ensures CMC development to meet FDA requirements.
AdvanCell has deep experience in running clinical trials for radioligand therapies.
Australia’s world-leading Nuclear Medicine expertise and infrastructure offers a smooth and competitive path for clinical development.